Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI versus FF in persistent asthma
2012-002797-32Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone furoate + vilanterol and fluticasone in persistent asthma (3 arms), sponsored by GSK. Primary endpoint: Weighted mean serial FEV1 over 0-24 hours post-dose at the end of the 12 week treatment period. Started Aug 2012; status: completed.
02
Drugs
fluticasone furoate + vilanterolfluticasone
03
Conditions
persistent asthma
Beyond the preview
Go deeper on 2012-002797-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002797-32.